Abstract
An open-label long-term Phase 3 study of CAM2029, an octreotide subcutaneous depot, in patients with acromegaly (ACROINNOVA 2): interim analysis of patient-reported outcomes
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have